A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 g in 1-through 3-year old Children with Peanut Allergy

Date Added
February 13th, 2026
PRO Number
Pro00149278
Researcher
Kelli Williams

List of Studies


Keywords
Allergy, Children's Health, Pediatrics
Summary

This study is a double‑blind, placebo‑controlled research study to evaluate the safety and effectiveness of a skin patch treatment for peanut allergy in children ages 1 to 3. The patch delivers a very small amount of peanut protein through the skin and is designed to help the immune system become less sensitive to peanuts over time.

Participation in the study will last approximately 34 weeks. Participation is voluntary, and participants may withdraw at any time.

Institution
MUSC
Recruitment Contact
Rohini Rao
(843) 792-0965
recruitment@musc.edu



-- OR --